The CCNY Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for the targeted disruption of the CCNY gene, which encodes Cyclin Y, a critical regulator of Wnt/??-catenin signal transduction. This polyclonal pool, derived from the Raji B lymphoblast cell line, offers a heterogeneous loss-of-function model that reflects the genetic variability inherent in polyclonal knockout populations, enabling robust functional studies without clonal selection bias. The product format facilitates scalable experiments requiring consistent knockout efficiency across bulk cultures, making it suitable for high-throughput screening and mechanistic dissection of Cyclin Y-dependent pathways in lymphoma biology.
The host Raji cell line is a suspension-adapted B lymphoblast model originally isolated from a Burkitt lymphoma patient and characterized by persistent Epstein-Barr virus (EBV) positivity. Widely employed in B-cell malignancy research, Raji cells retain key features of aggressive B-cell lymphoma, including constitutive activation of survival and proliferative signaling networks. The EBV-driven latency program and inherent dysregulation of cell cycle control mechanisms render Raji cells particularly sensitive to perturbations in oncogenic pathways, establishing a relevant cellular context for interrogating novel therapeutic targets and dissecting lymphoma pathogenesis at the molecular level.
Cyclin Y, the protein product of CCNY, functions as an essential cofactor for the cyclin-dependent kinase CDK14/PFTK1, forming an active complex that specifically phosphorylates the Wnt co-receptor LRP6 at critical serine residues. This phosphorylation event, occurring downstream of Wnt ligand stimulation (e.g., Wnt3a), potentiates Wnt/??-catenin signaling by promoting LRP6 signalosome assembly and subsequent inhibition of the ??-catenin destruction complex, which includes AXIN, APC, and GSK3??. Consequently, ??-catenin becomes stabilized and translocates to the nucleus, where it partners with TCF/LEF transcription factors to drive expression of target genes such as MYC and CCND1. Additionally, Cyclin Y-mediated signaling interfaces with PI3K/AKT pathways, as evidenced by AKT phosphorylation downstream of LRP6 activation, highlighting its integrative role in coordinating cell cycle progression and migration.
In the context of Burkitt lymphoma, aberrant Wnt/??-catenin activity is frequently observed and contributes to sustained proliferation and survival of malignant B cells. By eliminating CCNY function in Raji cells, this knockout model specifically disables the CDK14-dependent LRP6 phosphorylation axis, thereby attenuating ??-catenin stabilization and transcriptional output. This disruption is particularly relevant given the overexpression of Cyclin Y in certain lymphoma subtypes and its putative role in driving oncogenic phenotypes such as uncontrolled cell division and enhanced migratory capacity. The resulting cells provide a powerful platform for dissecting how Cyclin Y-mediated signal amplification influences lymphoma growth dynamics and for evaluating the dependency of EBV-transformed B cells on Wnt-driven transcriptional programs.
Researchers can employ these polyclonal knockout cells to investigate Wnt signaling mechanisms in lymphoma through a variety of downstream assays, including Western blot analysis of CCNY, ??-catenin, and phospho-LRP6 levels, RT-qPCR quantification of Wnt target genes (MYC, CCND1), and TOP/FOP flash luciferase reporter assays to measure ??-catenin-mediated transcription. Furthermore, flow cytometry-based cell cycle analysis and co-immunoprecipitation of the CCNY?CCDK14 complex enable detailed characterization of Cyclin Y??s role in proliferation and protein interactions, while migration and invasion assays assess metastatic potential. For in vivo applications, these cells can be used in xenograft tumor growth studies to evaluate therapeutic responses in the absence of CCNY. For further information and custom inquiries, please contact Ascent Research.
